ImmunityBio Inc. – Filings and Transcripts

NASDAQ: IBRX
Share price (10/15/26): $10.00
Market cap (10/15/26): $10.6 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Cambridge Equities, LP

News Filter

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

Shareholder Vote Results, Financial Statements or Exhibits

Signs Exclusive U.S. Agreement With Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Preliminary info

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Scanned paper annual report submission